ArticleMikrochimica acta2026
Serum KIM-1 molecular early warning radar: SERS combined with artificial intelligence for accurate early diagnosis of chronic kidney disease.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chronic kidney disease (CKD) has become a major global public health issue. Due to its insidious onset and atypical early symptoms, patients often fail to detect it in time and receive effective intervention. Therefore, conducting early screening and diagnosis is of great significance for delaying the progression of renal failure and reducing the burden on patients and society. Combining surface-enhanced Raman scattering (SERS) technology, immunochromatography and artificial intelligence algorithm, this study utilized serum kidney injury molecule-1 (KIM-1) molecule as a key biomarker to construct a serum-based CKD diagnostic model, aiming to achieve efficient and accurate CKD screening. A total of six models were included for comparative analysis, among which the extreme gradient boosting (XGBoost) model successfully achieved precise classification of CKD, with a classification accuracy of 98.42% and an area under the curve (AUC) of 99.96%. Furthermore, leave-one-out cross-validation was used to validate this model, with an overall classification accuracy of 96.79%. These results indicated that the model exhibited good stability and strong robustness. In conclusion, the artificial intelligence-driven immunochromatography SERS biosensing technology with serum KIM-1 molecule as the early warning radar is expected to become a new technical strategy for intelligent early screening and auxiliary diagnosis of CKD.
Indexed as
Identifiers
42120702What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.